Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ACST

Acasti Pharma (ACST) Stock Price, News & Analysis

Acasti Pharma logo

About Acasti Pharma Stock (NASDAQ:ACST)

Advanced Chart

Key Stats

Today's Range
$3.03
$3.14
50-Day Range
$2.56
$3.60
52-Week Range
$1.98
$3.60
Volume
12,261 shs
Average Volume
22,722 shs
Market Capitalization
$29.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Receive ACST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

ACST Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Craig-Hallum Sticks to Their Buy Rating for Acasti Pharma (ACST)
See More Headlines

ACST Stock Analysis - Frequently Asked Questions

Acasti Pharma Inc. (NASDAQ:ACST) released its earnings results on Friday, June, 21st. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.30.

Acasti Pharma shares reverse split on Monday, July 10th 2023.The 1-6 reverse split was announced on Monday, July 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acasti Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
6/21/2024
Today
7/13/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACST
CIK
1444192
Employees
32
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$8.00
Potential Upside/Downside
+221.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.44)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.85 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-13.61%
Return on Assets
-11.56%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.86
Quick Ratio
7.86

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.57 per share
Price / Book
0.47

Miscellaneous

Outstanding Shares
9,399,000
Free Float
8,770,000
Market Cap
$29.23 million
Optionable
Not Optionable
Beta
1.52
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:ACST) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners